Cerenome
Diagnostic testing and targeted radiotherapy development for central nervous system cancers.
$3.05
After-hours close+0.01 (+0.33%)
At close$3.04(−1.94%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions —Insiders —
Shares outstanding 6.88M · Float 6.81M
Institutions13F
No 13F holders on record.
Beneficial owners13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
InsidersForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.